Covid-19 vaccine: No adverse side-effects so far in 53 Oxford vaccine volunteers at Chandigarh's PGI
4 years, 2 months ago

Covid-19 vaccine: No adverse side-effects so far in 53 Oxford vaccine volunteers at Chandigarh's PGI

India Today  

No adverse side-effects have been reported among the volunteers of the Oxford-AstraZeneca vaccine have been observed so far, the Post Graduate Institute of Medical Education and Research has said. Fifty-three persons, participating in the Covid-19 vaccine trials at the Chandigarh’s PGIMER, have not reported any major side effects seven days after being vaccinated, a report in The Hindustan Times said. Of these, 65 had already been vaccinated since September 25 when the institute started administering the first dose of the Covid-19 vaccine candidate to volunteers. “Among 65 volunteers given the first dose, 53 participants have already completed seven days post-vaccination without any major side effects,” the spokesperson was quoted by saying by the report. Read: Covid-19 vaccine update: US drug controller publishes vaccine guidelines, Russia's Sputnik V in India The institute is likely to administer the Covid-19 vaccine to around 300 volunteers in phase 2 and 3 of the observer-blind, randomised, controlled study to determine the safety of Covishield and its immunogenicity in healthy Indian adults, the report added.

India Trials Volunteers Report Chandigarh Vaccine Oxford Pgimer Covishield  report  volunteers  phase  vaccine  chandigarhs  oxfordastrazeneca  pgi  trials  covid19  oxford  india  pgimer  institute  far  sideeffects  53  adverse

History of this topic

‘Still not over’: WHO cautions of COVID-19 threat ahead of summer holidays after US President Joe Biden tests positive
5 months ago

‘Still not over’: WHO cautions of COVID-19 threat ahead of summer holidays after US President Joe Biden tests positive

Live Mint  

New Delhi: With US President Joe Biden testing positive for COVID-19 before the Presidential elections, the World Health Organisation has warned the public that Covid is still not over. WHO director-general Tedros Adhanom Ghebreyesus issued a warning, stating that vaccination rates among health professionals and the over-60s—two demographics most at risk of dying from COVID—are alarmingly falling. Globally, 9.8 million …

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines
7 months, 2 weeks ago

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines

News 18  

In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine manufactured by the Serum Institute of India. At a press conference, the doctors, under the banner of the Awaken India Movement, …

AstraZeneca withdraws Covishield pointing to low demand, but did rare side effects also play a role?
7 months, 2 weeks ago

AstraZeneca withdraws Covishield pointing to low demand, but did rare side effects also play a role?

The Hindu  

Published : May 09, 2024 13:21 IST - 3 MINS READ The pharmaceutical giant AstraZeneca has reportedly withdrawn its COVID-19 vaccine Vaxzevria, also known as Covishield, worldwide, citing commercial reasons for the decision. Vaxzevria saved millions of lives AstraZeneca, who developed the vaccine with Oxford University, said it was “incredibly proud of the role Vaxzevria played in ending the global …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

Stopped manufacturing Covishield since December 2021, says Serum Institute
7 months, 2 weeks ago

Stopped manufacturing Covishield since December 2021, says Serum Institute

Hindustan Times  

Pune-based Serum Institute of India stopped manufacturing its anti-Covid-19 vaccine Covishield in 2021, according to a statement issued by the company on Wednesday after British-Swedish pharmaceutical manufacturer AstraZeneca announced it was withdrawing its vaccine against Covid, Vaxzevria, due to “commercial reasons” as demand for it decreased globally. Consequently, since December 2021, we have stopped the manufacturing and supply of additional …

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors
7 months, 2 weeks ago

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors

The Hindu  

At a time when the safety aspects of the Covishield vaccine have kicked up a row, a retrospective study by two doctors from Kozhikode has claimed that its risks are minimal in view of the benefits. The controversy arose after pharmaceutical company AstraZeneca admitted in the High Court of London, United Kingdom, that its vaccine against COVID-19 had the potential …

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’
7 months, 3 weeks ago

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’

The Hindu  

The controversy over the safety aspects of the Covishield vaccine reached the Supreme Court on Wednesday, May 1, 2024, with a petition seeking the constitution of an expert medical panel to study the risk factors. Now after the document filed in UK court by the developer of Covishield, we are compelled to think on the risk and hazardous consequences of …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
7 months, 3 weeks ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

New COVID variant JN.1: Health Ministry says no need for booster dose
1 year ago

New COVID variant JN.1: Health Ministry says no need for booster dose

The Hindu  

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India. India saw a single-day rise of 656 COVID-1 infections while the active cases have increased …

At least single dose vaccine prior to COVID-19 infection provided 60% protection against post-discharge mortality: ICMR study
1 year, 4 months ago

At least single dose vaccine prior to COVID-19 infection provided 60% protection against post-discharge mortality: ICMR study

The Hindu  

At least one dose of vaccine prior to COVID-19 infection provided 60% protection against post-discharge mortality, an Indian Council of Medical Research study on factors related to mortality within one year after discharge in hospitalised COVID-19 patients has found. Overall, the study’s findings suggest that a post-discharge mortality rate of 6.5% in patients hospitalised for COVID-19 warrants a vigilant follow-up. …

Amid Covid surge, Tricity short of vaccine doses
1 year, 8 months ago

Amid Covid surge, Tricity short of vaccine doses

Hindustan Times  

Amid a surge in Covid infections, the Tricity is facing a glaring lack of vaccine availability. Director, health services, Dr Suman Singh has confirmed that the Covid-19 vaccine is currently unavailable, and the department has already communicated this to the Government of India for additional supplies. According to data provided by the health department, a total of 10,89,773 first doses …

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects
1 year, 10 months ago

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects

Live Mint  

A well known British-Indian cardiologist has flagged the cardiovascular side effects of the Covishield vaccine. According to Dr Aseem Malhotra, the vaccine manufactured in India by the Serum Institute is ‘even worse’ than mRNA COVID-19 vaccines when it came to concerns such as heart attacks and strokes. Citing a comparison published in a peer-reviewed journal, he said that the Oxford-AstraZeneca …

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella
1 year, 10 months ago

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella

India TV News  

COVID-19 vaccine : Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday. "We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago," Ella said. Establishing the UW-Madison Global One Health Centre holds great significance as …

Multiple COVID vaccine side-effects: Health Ministry clears air on recent report
1 year, 11 months ago

Multiple COVID vaccine side-effects: Health Ministry clears air on recent report

Live Mint  

The Union Health Ministry has reiterated that only a small percentage of patients who receive the COVID-19 vaccine may develop serious adverse events depending on certain predisposing circumstances, refuting the reports of various side effects of the vaccine. According to a recent media report, the Central Drugs Standard Control Organization and the Indian Council of Medical Research have acknowledged "multiple …

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla
1 year, 11 months ago

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla

Firstpost  

Pune: Chief Executive Officer of Serum Institute of India, Adar Poonawalla, has said their Covovax vaccine will get approval as a booster dose against Covid-19 in the next 10 to 15 days. Poonawalla told the media that the vaccine works very well against the Omicron variant of coronavirus. Speaking to reporters on the sidelines of an event at the Bharati …

No second Covid-19 booster dose required: Report
1 year, 11 months ago

No second Covid-19 booster dose required: Report

Live Mint  

There is no need to take a second booster dose against Covid-19 infection, news agency ANI reported on Tuesday citing government sources. According to the data by the Union Health Ministry, a total of 220.11 crore vaccine doses have been administered in the country, of which 95.13 crore have taken the second dose while only 22.41 crore of the population …

Fact-check on vaccine-related misinformation
2 years ago

Fact-check on vaccine-related misinformation

China Daily  

Vaccine is a powerful weapon in the fight against COVID-19. As the second COVID booster becomes available for eligible people and the health authorities work to boost senior vaccination rates, misinformation about COVID-19 vaccines is also rising. The COVID-19 vaccines work by imitating an infection and can cause mild side effects, such as a fever or pain at the injection …

Fact-check on vaccine-related misinformation
2 years ago

Fact-check on vaccine-related misinformation

China Daily  

Vaccine is a powerful weapon in the fight against COVID-19. As the second COVID booster becomes available for eligible people and the health authorities work to boost senior vaccination rates, misinformation about COVID-19 vaccines is also rising. The COVID-19 vaccines work by imitating an infection and can cause mild side effects, such as a fever or pain at the injection …

COVID-19 vaccines offer significant protection against reinfection: Study
2 years, 1 month ago

COVID-19 vaccines offer significant protection against reinfection: Study

India TV News  

COVID-19 vaccine: A recent study revealed that people earlier infected with the SARS-CoV-2 virus still benefit from vaccination against COVID-19, gaining 60% to 94% protection against reinfection. “In our study, we find a significant vaccine effectiveness against SARS-CoV-2 reinfection, and this shows the importance of vaccination also for those who might be protected by natural immunity," said Katrine Finderup Nielsen …

Health Ministry not to procure fresh COVID-19 vaccines; surrenders ₹4,237 crore from vaccination budget
2 years, 2 months ago

Health Ministry not to procure fresh COVID-19 vaccines; surrenders ₹4,237 crore from vaccination budget

The Hindu  

The government’s COVID-19 vaccination programme is in its final leg with the Health Ministry deciding against procuring more vaccines as of now and surrendering ₹4,237 crore, or nearly 85% of the 2022-23 budget allocation for inoculation purposes, to the Finance Ministry. Official sources told PTI that more than 1.8 crore doses are still available with the governments at the Centre …

COVID-19: Corbevax to be given as boosters at vaccination centres from today
2 years, 4 months ago

COVID-19: Corbevax to be given as boosters at vaccination centres from today

Live Mint  

Hyderabad based-Biological E Ltd 's recently approved heterologous Covid-19 vaccine Corbevax to be available as a booster dose on the COWIN App in both public and private vaccination centres from 12 August, the firm said on 11 August. The Union Health Ministry approved Corbevax as India's first heterologous COVID-19 booster shot for 18 years and above after the six months …

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday
2 years, 4 months ago

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday

News 18  

Biological E. Ltd on Thursday said it has delivered 10 crore doses of its Covid-19 vaccine, Corbevax to the Centre so far which is expected to be available as a booster dose on the Cowin App in public and private vaccination centers from Friday. Corbevax was also approved by the Union Health Ministry as a heterologous Covid-19 booster dose under …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

Deccan Chronicle  

New Delhi: The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India Today  

The government has approved Biological E's Corbevax as a precautionary dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. "Corbevax will be considered as a precautionary dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India TV News  

Highlights Biological E's Corbevax has been approved as a booster or precaution dose. Covid vaccination: Biological E's Corbevax has been approved as a booster or precaution dose for those above the age of 18, and those who are fully vaccinated with either Covishield or Covaxin. "Corbevax will be considered as a precaution dose after completion of six months or 26 …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

COVID-19: Over 7.20 crore unutilized vaccine doses available with States, Union Territories says health ministry
2 years, 4 months ago

COVID-19: Over 7.20 crore unutilized vaccine doses available with States, Union Territories says health ministry

Firstpost  

The vaccination drive has been ramped up through the availability of more vaccines, advance visibility of vaccine availability to States and UTs for enabling better planning by them, and streamlining the vaccine supply chain New Delhi: The Ministry of Health and Family Welfare on Sunday informed that more than 7.20 crore balance and unutilized COVID-19 vaccine doses are still available …

Go For More Tests, Faster Vaccination: Worried by Uptick in Covid Graph, Centre's Advisory to 7 States
2 years, 4 months ago

Go For More Tests, Faster Vaccination: Worried by Uptick in Covid Graph, Centre's Advisory to 7 States

News 18  

Ramp up testing, promote Covid-appropriate behaviour and increase the pace of vaccination, the Centre has told Delhi and six states amid a spike in coronavirus cases, especially ahead of the festive season. The state must also closely monitor districts reporting higher cases, positivity rates and clusters to prevent further spread of infection and effective case management,” he stressed in the …

Covid-19 update: India sees another rise with 19,893 cases in 24 hrs
2 years, 4 months ago

Covid-19 update: India sees another rise with 19,893 cases in 24 hrs

Live Mint  

India on 4 August reported another rise in Covid-19 cases with 19,893 new infections. This sharp rise comes after India reported 17,135 Covid-19 on 3 August after a drop in infection a day prior with 13,734 cases and 34 deaths. Under the Covid-19 nationwide vaccination program, a total of 38,20,676 doses were administered in the last 24 hours taking India's …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

4 Cr Eligible Beneficiaries Havn't Taken Even Single Dose of Covid-19 Vaccine as on July 18: Govt
2 years, 5 months ago

4 Cr Eligible Beneficiaries Havn't Taken Even Single Dose of Covid-19 Vaccine as on July 18: Govt

News 18  

An estimated 4 crore eligible beneficiaries have not taken even a single dose of COVID-19 vaccine as on July 18, Minister of State for Health Bharati Pravin Pawar informed the Lok Sabha on Friday. A total of 1,78,38,52,566 vaccine doses have been administered free of cost in Government Covid Vaccination Centres till July 18, she said in a written reply. …

India reports over 20,000 new COVID-19 cases after 145 days
2 years, 5 months ago

India reports over 20,000 new COVID-19 cases after 145 days

The Hindu  

Daily COVID-19 cases in India were recorded over 20,000 after a gap of 145 days while the active cases increased to 1,36,076, according to the Union Health Ministry data updated on Thursday, July 14, 2022. A total of 20,139 new COVID-19 cases were reported in a span of 24 hours, pushing the total tally of cases to 4,36,89,989. The active …

Free COVID-19 booster shots for all adults for 75 days from July 15 at government centres
2 years, 5 months ago

Free COVID-19 booster shots for all adults for 75 days from July 15 at government centres

The Hindu  

As part of the Azadi Ka Amrit Mahotsav celebrations, free precaution doses of COVID-19 vaccines will be available for all citizens above 18 years of age at government vaccination centres from July 15 for 75 days, Anurag Singh Thakur, Union Minister of Information and Broadcasting, announced on July 13, following a meeting of the Union Cabinet. India’s cumulative COVID-19 vaccination …

India logs 16,678 new COVID-19 infections; active cases rise to 1,30,713
2 years, 5 months ago

India logs 16,678 new COVID-19 infections; active cases rise to 1,30,713

Firstpost  

The daily positivity rate now stands at 5.99 per cent while the weekly positivity is 4.18 per cent, according to the health ministry New Delhi: With 16,678 new coronavirus infections being reported in a day, India’s total tally of COVID-19 cases rose to 4,36,39,329, while the active cases increased to 1,30,713, according to the Union Health Ministry data updated on …

Active COVID-19 cases increase to 1,28,690
2 years, 5 months ago

Active COVID-19 cases increase to 1,28,690

The Hindu  

With 18,257 new coronavirus infections being reported in a day, India's total tally of COVID-19 cases rose to 4,36,22,651, while the active cases increased to 1,28,690, according to the Union Health Ministry data updated on July 10, 2022. The active cases comprise 0.30% of the total infections, while the national COVID-19 recovery rate was recorded at 98.50%, the Ministry said. …

India Logs Over 18,000 New Covid-19 Infections in 24 Hrs; Active Cases Cross 1L Mark
2 years, 5 months ago

India Logs Over 18,000 New Covid-19 Infections in 24 Hrs; Active Cases Cross 1L Mark

News 18  

India logged over 18,000 new coronavirus infections in a single day after a gap of 130 days, taking the COVID-19 tally to 4,34,52,164, according to the Union Health Ministry data updated on Thursday. A total 18,819 new Covid cases were reported in a span of 24 hours while the death toll climbed to 5,25,116 with 39 new fatalities, the data …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

India Reports 17,336 Fresh COVID-19 Cases in 24 Hours, 13 Fatalities
2 years, 6 months ago

India Reports 17,336 Fresh COVID-19 Cases in 24 Hours, 13 Fatalities

News 18  

India reported a single-day rise of more than 17,000 fresh COVID-19 cases on Friday after a gap of over four months, recording a 30 per cent jump in daily cases, according to the Union Health Ministry. A total 17,336 coronavirus cases were reported in a span of 24 hours, taking the total infection tally to 4,33,62,294, while the death toll …

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study
2 years, 6 months ago

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study

The Hindu  

COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic. In the first year of the vaccination programme, 19.8 million out of a potential 31.4 million COVID-19 deaths were prevented worldwide, according to …

Vaccination advisory group recommends reducing COVID-19 booster dose gap to 6 months
2 years, 6 months ago

Vaccination advisory group recommends reducing COVID-19 booster dose gap to 6 months

The Hindu  

The Standing Technical Sub-Committee of the NTAGI on Thursday recommended reducing the gap between the second and precaution doses of COVID-19 vaccines from the current nine to six months, official sources said. The government advisory panel, which met on Thursday, also reviewed the findings of a study by the Christian Medical College in Vellore on the feasibility of allowing as …

India reports 12,213 new COVID-19 cases, 11 deaths
2 years, 6 months ago

India reports 12,213 new COVID-19 cases, 11 deaths

The Hindu  

The single day rise in new coronavirus infections were recorded over 12,000 after 111 days, registering 38.4 per cent jump in daily cases while the active cases have increased to 58,215, according to the Union Health Ministry data on Thursday, June 13, 2022. A total 12,213 cases were reported in a span of 24 hours, taking India's total tally of …

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap
2 years, 6 months ago

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap

News 18  

Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses from the current nine to six months. The agenda for the NTAGI's Standing Technical Sub-Committee meeting includes a discussion on a study by the CMC Vellore …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 6 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Discover Related